Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.

The optional followup period for this study is 1 year after the last vaccination.

Inclusion Criteria:

• Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
• Patient must not be pregnant 3 days prior to enrollment

Exclusion Criteria:

• Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
• Patient has had their spleen removed or has a history of autoimmune disorders
• Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
• Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
• Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
• Patient has a known history of Hepatitis B or C
• Patient has received a vaccine for any disease or condition within one month of enrollment
• Patient has a primary central nervous system tumor.